Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects

被引：11

作者：

Chang, Joshua ^{[1
,2
]}

Werth, Victoria P. ^{[1
,2
]}

机构：

[1] Corporal Michael J Crescenz Philadelphia VA Med C, Dermatol Sect, Philadelphia, PA USA

[2] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2016年 / 12卷 / 10期

关键词：

Cutaneous lupus erythematosus; topical calcineurin inhibitors; antimalarials; immunosuppressives; immunomodulators; biologics; Cutaneous Lupus Erythematosus Disease Area and Severity IndexTM (CLASITM); QUALITY-OF-LIFE; B-LYMPHOCYTE STIMULATOR; VITAMIN-D ANALOGS; PULSED DYE-LASER; DISCOID LUPUS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; ANTIMALARIAL-DRUGS; DISEASE SEVERITY; HYDROXYCHLOROQUINE RETINOPATHY;

D O I：

10.1080/1744666X.2016.1188006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction: Treatment and prevention are of critical importance in patients with cutaneous lupus erythematosus (CLE), as the disease can have a devastating effect on patient well-being and quality of life.Areas Covered: We conducted a selective search of the PubMed database for articles published between December 2010 and November 2015. This review encompasses both non-pharmaceutical (photoprotection, smoking cessation, drug withdrawal, and vitamin D replacement) and pharmaceutical (topicals, antimalarials, immunosuppressives, biologics, etc.) interventions used in the treatment of CLE.Expert Commentary: Recent work has expanded our understanding of established therapies as well as introduced new treatments for consideration, though existing medications still prove inadequate for a subset of patients. Changes in trial design may help to alleviate this issue.

引用

页码：1109 / 1121

页数：13

共 50 条

[41] Immunotherapy of glioblastoma: recent advances and future prospects
Yuan, Boyang
Wang, Guoqing
Tang, Xin
Tong, Aiping
Zhou, Liangxue
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)
[42] Epidemiology of sarcoidosis: Recent advances and future prospects
Rybicki, Benjamin A.
Iannuzzi, Michael C.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 28 (01) : 22 - 35
[43] Linear cutaneous lupus erythematosus: a subset of childhood cutaneous lupus erythematosus
Gaitanis, G.
Nomikos, K.
Chaniotakis, I.
Stergiopoulou, C.
Zioga, A.
Bassukas, I.
LUPUS, 2009, 18 (08) : 759 - 761
[44] Biologics in systemic lupus erythematosus: current options and future perspectives
Yusof, Yuzaiful Md
Vital, Edward M.
Emery, Paul
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (08) : 440 - 447
[45] Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects
Moura Filho, Jucelio Pereira
Peixoto, Raiza Luna
Martins, Lvia Gomes
de Melo, Sillas Duarte
de Carvalho, Ligiana Leite
Pereira, Ana Karine F. da Trindade C.
Medeiros Freire, Eutilia Andrade
ANAIS BRASILEIROS DE DERMATOLOGIA, 2014, 89 (01) : 118 - 125
[46] Cutaneous lupus erythematosus: recent lessons from animal models
Ghoreishi, M.
Dutz, J. P.
LUPUS, 2010, 19 (09) : 1029 - 1035
[47] Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies
Joerg Wenzel
Nature Reviews Rheumatology, 2019, 15 : 519 - 532
[48] Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies
Wenzel, Joerg
NATURE REVIEWS RHEUMATOLOGY, 2019, 15 (09) : 519 - 532
[49] Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects
Alexis Mathian
Miguel Hie
Fleur Cohen-Aubart
Zahir Amoura
Drugs, 2015, 75 : 835 - 846
[50] Telomeres and telomerase: Relevance and future prospects in systemic lupus erythematosus
Georgin-Lavialle, S.
Aouba, A.
Lepelletier, Y.
Gabet, A. -S.
Hermine, O.
REVUE DE MEDECINE INTERNE, 2010, 31 (05): : 345 - 352

← 1 2 3 4 5 →